PLA2G4A

Across TCGA pan-cancer cohorts, PLA2G4A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLA2G4A data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PLA2G4A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2G4A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and SCLC are the cancer types where PLA2G4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.250	0.778	.007	12	view →
UCEC	DFS	Median	All	0.913	0.622	.026	8	view →
SCLC	DFS	Median	III,IV	0.137	0.546	.042	6	view →
GBM	OS	Median	All	0.070	0.416	.003	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLA2G4A–LUSC (OS)

Open the LUSC breakdown →